Final - February 25, 2019

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

page 1 of 2

PRESIDER/PRESENTER(s)

8:00 Dr. Jose Romero (ACIP Chair)

Dr. Amanda Cohn (ACIP Executive Secretary; CDC)

8:20 Japanese Encephalitis Vaccine

Introduction

Background and review

Updated recommendations for U.S. travelers

Accelerated primary series in adults

Booster dose recommendations

Dr. Chip Walter (ACIP, WG Chair)

Dr. Susan Hills (CDC/NCEZID)

Dr. Susan Hills (CDC/NCEZID)

Dr. Susan Hills (CDC/NCEZID)

Dr. Susan Hills (CDC/NCEZID)

9:20

9:30 Anthrax Vaccines

Introduction

AV7909 (NuThrax)

Preexposure AVA booster dose interval

Dr. David Stephens (ACIP, WG Chair)

Dr. William Bower (CDC/NCEZID)

Dr. William Bower (CDC/NCEZID)

10:30

10:40 Influenza Vaccines

Introduction

Surveillance update

VE update

Afluria quadrivalent for children aged 6 through 59 months

Inactivated influenza vaccine and spontaneous abortion in the 

Vaccine Safety Datalink

Summary and work group considerations

Dr. Chip Walter

Ms. Lynnette Brammer (CDC/NCIRD)

Dr. Brendan Flannery (CDC/NCIRD)

Dr. Gregg Sylvester (Seqirus)

Dr. James Donahue (Marshfield Clinic)

Dr. Lisa Grohskopf (CDC/NCIRD)

12:00

1:00 Human Papillomavirus Vaccines

Introduction 

Overview and background 

Impact and cost effectiveness of mid-adult HPV vaccination 

Overview of health economic results from 4 modeling groups 

Mid-adult HPV vaccination: patient values and acceptability 

Program and vaccine provider surveys

Work group considerations

Dr. Peter Szilagyi (ACIP, WG Chair)

Dr. Lauri Markowitz (CDC/NCIRD)

Dr. Marc Brisson (Laval University)

Dr. Harrell Chesson (CDC/NCHHSTP)

Dr. Nancy McClung (CDC/NCIRD)

Dr. Elissa Meites (CDC/NCIRD)

Dr. Lauri Markowitz (CDC/NCIRD)

2:30

2:40 Combination Vaccines

Introduction

Immunogenicity and safety of a pediatric hexavalent vaccine

Hib vaccines in AI/AN population

Summary, review of work group considerations

Dr. Kelly Moore (ACIP, WG Chair)

Dr. Andrew Lee (Merck) 

Dr. Laura Hammitt (Johns Hopkins University)

Dr. Sara Oliver (CDC/NCIRD)

3:30

3:40

4:55

5:00 VOTES

Japanese Encephalitis Vaccine

Anthrax Vaccines

Dr. Susan Hills (CDC/NCEZID)

Dr. William Bower (CDC/NCEZID)

5:30 Adjourn

Break

Break

Break

Public Comment

1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium

Atlanta, Georgia 30329 

AGENDA ITEM

February 27-28, 2019

Lunch

Break

Break

Wednesday, February 27

Welcome & Introductions

This document has been archived for historical purposes. (2/25/2019)
Final - February 25, 2019

page 2 of 2

8:30 Pneumococcal Vaccines

Introduction 

PCV13 direct and indirect effects on serotype 3 disease

PCV13 direct effects on pneumonia hospitalizations in adults 

Comparison of economic analyses of PCV13 use among adults ≥65 

years old 

GRADE and Evidence to Recommendations (EtR) for PCV13 use 

among adults ≥65 years old in the context of indirect effects 

experience to date

Dr. Grace Lee (ACIP, WG Chair)

Dr. Tamara Pilishvili (CDC/NCIRD)

Dr. Fernanda Lessa (CDC/NCIRD)

Dr. Andrew Leidner (CDC/NCIRD)

Dr. Almea Matanock (CDC/NCIRD)

10:30

10:40 Meningococcal Vaccines

Introduction

Immunogenicity and safety of a MenB-FHbp booster dose

Immunogenicity and safety of a MenB-4C booster dose

GRADE and Evidence to Recommendations Framework for MenB 

booster doses

Work Group interpretation of data, considerations, and next steps

Dr. David Stephens (ACIP, WG Chair)

Dr. Paul Balmer (Pfizer)

Dr. Phil Watson (GSK)

Dr. Catherine Bozio (CDC/NCIRD)

Dr. Sarah Mbaeyi (CDC/NCIRD)

11:55

1:00 Zoster Vaccines

Introduction

Zoster vaccine uptake and supply

RZV safety update

Dr. Kelly Moore (ACIP, WG Chiar)

Dr. Kathleen Dooling (CDC/NCIRD)

Dr. Tom Shimabukuro (CDC/NCEZID)

1:40 Hepatitis Vaccines

Introduction

Background: HepA vaccines and persons with HIV infection 

GRADE: Use of HepA vaccines among persons with HIV infection

Evidence to Recommendation Framework: Use of HepA vaccines 

among persons with HIV infection

Dr. Kelly Moore (ACIP, WG Chair)

Dr. Mark Weng (CDC/NCHHSTP)

Ms. Alaya Koneru (CDC/NCHHSTP)

Dr. Mark Weng (CDC/NCHHSTP)

2:35 Vaccine Supply

2:40 Adjourn

Acronyms

AI/AN American Indian/Alaska Native 

AVA

CDC

CMS

DoD

DVA

EtR

FDA

GRADE

Hib

HRSA

IHS

MenB

NCHHSTP

NCIRD

NCEZID

NVPO

PCV13

RZV

WG

Grading of Recommendations Assessment, Development and Evaluation

Centers for Medicare and Medicaid Services 

Food and Drug Administration

Department of Veterans Affairs

Recombinant zoster vaccine

National Center for Emerging and Zoonotic Diseases [of CDC/OID]

National Center for Immunization & Respiratory Diseases [of CDC/OID] 

Work Group

National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID] 

Serogroup B meningococcal vaccine

13-valent pneumococcal conjugate vaccine 

Indian Health Service

Evidence to Recommendations Framework

Haemophilus influenzae type b

Department of Defense

National Vaccine Program Office

Thursday, February 28

8:00 Agency Updates & Unfinished Business

CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO

Health Resources and Services Administration

Centers for Disease Control & Prevention

Anthrax vaccine absorbed

Break

Lunch

Dr. Nancy Messonnier (CDC/NCIRD); Ex Officio Members

This document has been archived for historical purposes. (2/25/2019)